CynoCure™ Therapeutic Antibody Discovery Platform
Creative Biolabs is dedicated to accelerating canine monoclonal antibody discovery for veterinary medicine and transforming canine health through antibody innovation. We recognize the growing demand for innovative biologics to address the unmet medical needs of companion animals. Our CynoCure™ Therapeutic Antibody Discovery Platform is purpose-built for canine monoclonal antibody (mAb) discovery. Tailored to the unique immunological landscape of dogs, our platform provides biopharma, veterinary biotech, and research organizations with a reliable, streamlined solution for therapeutic antibody discovery.
Key Features of CynoCure™ Platform
Our platform integrates cutting-edge molecular technologies with a streamlined discovery-to-validation workflow. Key advantages include:
Service Workflow
| Workflow | Description |
|---|---|
| Target Strategy & Validation | We partner with you to define project goals, assays, and the optimal screening strategy. |
| Library Panning & Hit Identification | We leverage the full power of the CynoCure™ library to isolate a diverse panel of high-quality hits. |
| High-Throughput Characterization | Hits are rigorously screened and characterized for affinity, specificity, and function to identify top performers. |
| Lead Optimization & Engineering | Promising leads are engineered to create best-in-class therapeutic candidates that meet your precise specifications. |
| Candidate Delivery | We deliver a comprehensive data package with fully characterized, production-ready antibody candidates, accelerating your move into preclinical development. |
R&D Capabilities
Our scientific team brings extensive expertise in veterinary immunology, protein engineering, and therapeutic antibody development. With a fully integrated R&D workflow, we ensure each project benefits from advanced discovery strategies and rigorous validation.
- Target Biology Expertise: Deep understanding of canine immune pathways and disease models.
- Antibody Engineering: Optimization for affinity, stability, and reduced immunogenicity.
- Comprehensive Assays: Binding, neutralization, cell-based, and functional studies to validate candidate performance.
- Cross-Disciplinary Collaboration: Integration of molecular biology, bioinformatics, and veterinary science.
Why Canine Therapeutic Antibodies?
Monoclonal antibodies have revolutionized human medicine, which are transforming veterinary therapeutics. Dogs not only represent an important market but also serve as beloved family members whose health and quality of life are increasingly prioritized. Our platform empowers clients to lead in this new era of canine precision medicine. Antibody-based therapies offer:
Partner with Creative Biolabs
Your groundbreaking research deserves a world-class discovery partner. By leveraging Creative Biolabs' CynoCure™ platform, you can de-risk your pipeline, shorten your development timelines, and create safer, more effective therapies for dogs.
Contact our scientific team today to discuss your project and learn how CynoCure™ can accelerate your path to the clinic.